Protein piccolo (PCLO)
Homo sapiens — UniProt Q9Y6V0
Gene: PCLOHomo sapiensSwissProt reviewed
Data last refreshed: (UniProt release unknown)
Key facts
Protein piccolo (PCLO) is a protein from Homo sapiens identified by UniProt accession Q9Y6V0, 5142 residues long. MolForge cross-references it against 0 known binders and 115 disease associations.
- UniProt accession: Q9Y6V0; gene symbol PCLO.
- Organism: Homo sapiens.
- Length: 5142 amino acids.
- Top disease associations (Open Targets): pontocerebellar hypoplasia type 3, bipolar disorder and unipolar depression.
- 3D structure: AlphaFold model available.
Target properties
| Protein name | Protein piccolo |
|---|---|
| UniProt accession | Q9Y6V0 |
| Gene | PCLO |
| Organism | Homo sapiens |
| Length | 5142 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | — |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|---|
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (115)
Diseases linked to this target (Open Targets).
- pontocerebellar hypoplasia type 3 · score 0.62
- bipolar disorder · score 0.39
- unipolar depression · score 0.39
- vital capacity · score 0.35
- schizophrenia · score 0.34
- wellbeing measurement · score 0.31
- major depressive disorder · score 0.30
- grip strength measurement · score 0.29
- attention deficit hyperactivity disorder · score 0.29
- autism spectrum disorder · score 0.29
3D Structure (10)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|---|---|---|---|
| AF-Q9Y6V0-F20 | alphafold | PREDICTED | 51.22 | — |
| AF-Q9Y6V0-F19 | alphafold | PREDICTED | 48.61 | — |
| AF-Q9Y6V0-F17 | alphafold | PREDICTED | 48.48 | — |
| AF-Q9Y6V0-F18 | alphafold | PREDICTED | 48.29 | — |
| AF-Q9Y6V0-F6 | alphafold | PREDICTED | 46.38 | — |
| AF-Q9Y6V0-F5 | alphafold | PREDICTED | 46.37 | — |
| AF-Q9Y6V0-F4 | alphafold | PREDICTED | 46.28 | — |
| AF-Q9Y6V0-F13 | alphafold | PREDICTED | 45.50 | — |
Experimental structures are not indexed in MolForge yet — search RCSB PDB for Q9Y6V0.
Amino-acid sequence (5142 residues)
MGNEASLEGE GLPEGLAAAA AAGGGASGAG SPSHTAIPAG MEADLSQLSE EERRQIAAVM SRAQGLPKGS VPPAAAESPS MHRKQELDSS HPPKQSGRPP DPGRPAQPGL SKSRTTDTFR SEQKLPGRSP STISLKESKS RTDLKEEHKS SMMPGFLSEV NALSAVSSVV NKFNPFDLIS DSEASQEETT KKQKVVQKEQ GKPEGIIKPP LQQQPPKPIP KQQGPGRDPL QQDGTPKSIS SQQPEKIKSQ PPGTGKPIQG PTQTPQTDHA KLPLQRDASR PQTKQADIVR GESVKPSLPS PSKPPIQQPT PGKPPAQQPG HEKSQPGPAK PPAQPSGLTK PLAQQPGTVK PPVQPPGTTK PPAQPLGPAK PPAQQTGSEK PSSEQPGPKA LAQPPGVGKT PAQQPGPAKP PTQQVGTPKP LAQQPGLQSP AKAPGPTKTP VQQPGPGKIP AQQAGPGKTS AQQTGPTKPP SQLPGPAKPP PQQPGPAKPP PQQPGSAKPP SQQPGSTKPP PQQPGPAKPS PQQPGSTKPP SQQPGSAKPS AQQPSPAKPS AQQSTKPVSQ TGSGKPLQPP TVSPSAKQPP SQGLPKTICP LCNTTELLLH VPEKANFNTC TECQTTVCSL CGFNPNPHLT EVKEWLCLNC QMKRALGGDL APVPSSPQPK LKTAPVTTTS AVSKSSPQPQ QTSPKKDAAP KQDLSKAPEP KKPPPLVKQP TLHGSPSAKA KQPPEADSLS KPAPPKEPSV PSEQDKAPVA DDKPKQPKMV KPTTDLVSSS SATTKPDIPS SKVQSQAEEK TTPPLKTDSA KPSQSFPPTG EKVSPFDSKA IPRPASDSKI ISHPGPSSES KGQKQVDPVQ KKEEPKKAQT KMSPKPDAKP MPKGSPTPPG PRPTAGQTVP TPQQSPKPQE QSRRFSLNLG SITDAPKSQP TTPQETVTGK LFGFGASIFS QASNLISTAG QPGPHSQSGP GAPMKQAPAP SQPPTSQGPP KSTGQAPPAP AKSIPVKKET KAPAAEKLEP KAEQAPTVKR TETEKKPPPI KDSKSLTAEP QKAVLPTKLE KSPKPESTCP LCKTELNIGS KDPPNFNTCT ECKNQVCNLC GFNPTPHLTE IQEWLCLNCQ TQRAISGQLG DIRKMPPAPS GPKASPMPVP TESSSQKTAV PPQVKLVKKQ EQEVKTEAEK VILEKVKETL SMEKIPPMVT TDQKQEESKL EKDKASALQE KKPLPEEKKL IPEEEKIRSE EKKPLLEEKK PTPEDKKLLP EAKTSAPEEQ KHDLLKSQVQ IAEEKLEGRV APKTVQEGKQ PQTKMEGLPS GTPQSLPKED DKTTKTIKEQ PQPPCTAKPD QVEPGKEKTE KEDDKSDTSS SQQPKSPQGL SDTGYSSDGI SSSLGEIPSL IPTDEKDILK GLKKDSFSQE SSPSSPSDLA KLESTVLSIL EAQASTLADE KSEKKTQPHE VSPEQPKDQE KTQSLSETLE ITISEEEIKE SQEERKDTFK KDSQQDIPSS KDHKEKSEFV DDITTRREPY DSVEESSESE NSPVPQRKRR TSVGSSSSDE YKQEDSQGSG EEEDFIRKQI IEMSADEDAS GSEDDEFIRN QLKEISSSTE SQKKEETKGK GKITAGKHRR LTRKSSTSID EDAGRRHSWH DEDDEAFDES PELKYRETKS QESEELVVTG GGGLRRFKTI ELNSTIADKY SAESSQKKTS LYFDEEPELE MESLTDSPED RSRGEGSSSL HASSFTPGTS PTSVSSLDED SDSSPSHKKG ESKQQRKARH RPHGPLLPTI EDSSEEEELR EEEELLKEQE KQREIEQQQR KSSSKKSKKD KDELRAQRRR ERPKTPPSNL SPIEDASPTE ELRQAAEMEE LHRSSCSEYS PSIESDPEGF EISPEKIIEV QKVYKLPTAV SLYSPTDEQS IMQKEGSQKA LKSAEEMYEE MMHKTHKYKA FPAANERDEV FEKEPLYGGM LIEDYIYESL VEDTYNGSVD GSLLTRQEEE NGFMQQKGRE QKIRLSEQIY EDPMQKITDL QKEFYELESL HSVVPQEDIV SSSFIIPESH EIVDLGTMVT STEEERKLLD ADAAYEELMK RQQMQLTPGS SPTQAPIGED MTESTMDFDR MPDASLTSSV LSGASLTDST SSATLSIPDV KITQHFSTEE IEDEYVTDYT REIQEIIAHE SLILTYSEPS ESATSVPPSD TPSLTSSVSS VCTTDSSSPI TTLDSITTVY TEPVDMITKF EDSEEISSST YFPGSIIDYP EEISVSLDRT APPDGRASAD HIVISLSDMA SSIIESVVPK PEGPVADTVS TDLLISEKDP VKKAKKETGN GIILEVLEAY RDKKELEAER TKSSLSETVF DHPPSSVIAL PMKEQLSTTY FTSGETFGQE KPASQLPSGS PSVSSLPAKP RPFFRSSSLD ISAQPPPPPP PPPPPPPPPP PPPPPPLPPP TSPKPTILPK KKLTVASPVT TATPLFDAVT TLETTAVLRS NGLPVTRICT TAPPPVPPKP SSIPSGLVFT HRPEPSKPPI APKPVIPQLP TTTQKPTDIH PKPTGLSLTS SMTLNLVTSA DYKLPSPTSP LSPHSNKSSP RFSKSLTETY VVITLPSEPG TPTDSSASQA ITSWPLGSPS KDLVSVEPVF SVVPPVTAVE IPISSEQTFY ISGALQTFSA TPVTAPSSFQ AAPTSVTQFL TTEVSKTEVS ATRSTAPSVG LSSISITIPP EPLALDNIHL EKPQYKEDGK LQLVGDVIDL RTVPKVEVKT TDKCIDLSAS TMDVKRQITA NEVYGKQISA VQPSIINLSV TSSIVTPVSL ATETVTFVTC TASASYTTGT ESLVGAEHAM TTPLQLTTSK HAEPPYRIPS DQVFPIAREE APINLSLGTP AHAVTLAITK PVTVPPVGVT NGWTDSTVSQ GITDGEVVDL STTKSHRTVV TMDESTSSVM TKIIEDEKPV DLTAGRRAVC CDVVYKLPFG RSCTAQQPAT TLPEDRFGYR DDHYQYDRSG PYGYRGIGGM KPSMSDTNLA EAGHFFYKSK NAFDYSEGTD TAVDLTSGRV TTGEVMDYSS KTTGPYPETR QVISGAGIST PQYSTARMTP PPGPQYCVGS VLRSSNGVVY SSVATPTPST FAITTQPGSI FSTTVRDLSG IHTADAVTSL PAMHHSQPMP RSYFITTGAS ETDIAVTGID ISASLQTITM ESLTAETIDS VPTLTTASEV FPEVVGDESA LLIVPEEDKQ QQQLDLEREL LELEKIKQQR FAEELEWERQ EIQRFREQEK IMVQKKLEEL QSMKQHLLFQ QEEERQAQFM MRQETLAQQQ LQLEQIQQLQ QQLHQQLEEQ KIRQIYQYNY DPSGTASPQT TTEQAILEGQ YAALEGSQFW ATEDATTTAS AVVAIEIPQS QGWYTVQSDG VTQYIAPPGI LSTVSEIPLT DVVVKEEKQP KKRSSGAKVR GQYDDMGENM TDDPRSFKKI VDSGVQTDDE DATDRSYVSR RRRTKKSVDT SVQTDDEDQD EWDMPTRSRR KARVGKYGDS MTEADKTKPL SKVSSIAVQT VAEISVQTEP VGTIRTPSIR ARVDAKVEII KHISAPEKTY KGGSLGCQTE ADSDTQSPQY LSATSPPKDK KRPTPLEIGY SSHLRADSTV QLAPSPPKSP KVLYSPISPL SPGKALESAF VPYEKPLPDD ISPQKVLHPD MAKVPPASPK TAKMMQRSMS DPKPLSPTAD ESSRAPFQYT EGYTTKGSQT MTSSGAQKKV KRTLPNPPPE EISTGTQSTF STMGTVSRRR ICRTNTMARA KILQDIDREL DLVERESAKL RKKQAELDEE EKEIDAKLRY LEMGINRRKE ALLKEREKRE RAYLQGVAED RDYMSDSEVS STRPTRIESQ HGIERPRTAP QTEFSQFIPP QTQTESQLVP PTSPYTQYQY SSPALPTQAP TSYTQQSHFE QQTLYHQQVS PYQTQPTFQA VATMSFTPQV QPTPTPQPSY QLPSQMMVIQ QKPRQTTLYL EPKITSNYEV IRNQPLMIAP VSTDNTFAVS HLGSKYNSLD LRIGLEERSS MASSPISSIS ADSFYADIDH HTPRNYVLID DIGEITKGTA ALSTAFSLHE KDLSKTDRLL RTTETRRSQE VTDFLAPLQS SSRLHSYVKA EEDPMEDPYE LKLLKHQIKQ EFRRGTESLD HLAGLSHYYH ADTSYRHFPK SEKYSISRLT LEKQAAKQLP AAILYQKQSK HKKSLIDPKM SKFSPIQESR DLEPDYSSYM TSSTSSIGGI SSRARLLQDD ITFGLRKNIT DQQKFMGSSL GTGLGTLGNT IRSALQDEAD KPYSSGSRSR PSSRPSSVYG LDLSIKRDSS SSSLRLKAQE AEALDVSFSH ASSSARTKPT SLPISQSRGR IPIVAQNSEE ESPLSPVGQP MGMARAAAGP LPPISADTRD QFGSSHSLPE VQQHMREESR TRGYDRDIAF IMDDFQHAMS DSEAYHLRRE ETDWFDKPRE SRLENGHGLD RKLPERLVHS RPLSQHQEQI IQMNGKTMHY IFPHARIKIT RDSKDHTVSG NGLGIRIVGG KEIPGHSGEI GAYIAKILPG GSAEQTGKLM EGMQVLEWNG IPLTSKTYEE VQSIISQQSG EAEICVRLDL NMLSDSENSQ HLELHEPPKA VDKAKSPGVD PKQLAAELQK VSLQQSPLVL SSVVEKGSHV HSGPTSAGSS SVPSPGQPGS PSVSKKKHGS SKPTDGTKVV SHPITGEIQL QINYDLGNLI IHILQARNLV PRDNNGYSDP FVKVYLLPGR GQVMVVQNAS AEYKRRTKHV QKSLNPEWNQ TVIYKSISME QLKKKTLEVT VWDYDRFSSN DFLGEVLIDL SSTSHLDNTP RWYPLKEQTE SIDHGKSHSS QSSQQSPKPS VIKSRSHGIF PDPSKDMQVP TIEKSHSSPG SSKSSSEGHL RSHGPSRSQS KTSVTQTHLE DAGAAIAAAE AAVQQLRIQP TKPPNHRPAE SSVSTGSSGS SFGSGYSVDS EGSSSTAGET NLFPIPRIGK MGQNGQEPVK QPGVGVGLAD TEAKTQVMGE IKIALKKEMK TDGEQLIVEI LQCRNITYKF KSPDHLPDLY VKIYVMNIST QKKVIKKKTR VCRHDREPSF NETFRFSLSP AGHSLQILLF SNGGKFMKKT LIGEACIWLD KVDLRKRIVN WHKLLVSPTQ TH
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
Which diseases are associated with PCLO?
The strongest Open Targets associations for PCLO are pontocerebellar hypoplasia type 3, bipolar disorder, unipolar depression, vital capacity and schizophrenia.
How long is the PCLO protein?
The Homo sapiens PCLO protein (UniProt Q9Y6V0) is 5142 amino acids long.
Browse: Targets: P · all protein targets A–Z · drugs A–Z.
Sources
- UniProtKB Q9Y6V0 — name, gene, function, sequence, keywords (CC BY 4.0)
- AlphaFold DB Q9Y6V0 — predicted 3D structure (CC BY 4.0)
- Open Targets Platform — disease associations and tractability (CC0)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.